Kyung Dong Pharmaceutical Co. Ltd

KQ:011040 Korea Pharmaceuticals
Market Cap
$87.86 Million
₩128.65 Billion KRW
Market Cap Rank
#21239 Global
#991 in Korea
Share Price
₩5470.00
Change (1 day)
-0.18%
52-Week Range
₩5290.00 - ₩6200.00
All Time High
₩14206.86
Categories
Companies in Korea Pharmaceuticals
About

Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, ant… Read more

Kyung Dong Pharmaceutical Co. Ltd (011040) - Net Assets

Latest net assets as of September 2025: ₩217.26 Billion KRW

Based on the latest financial reports, Kyung Dong Pharmaceutical Co. Ltd (011040) has net assets worth ₩217.26 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩291.47 Billion) and total liabilities (₩74.22 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩217.26 Billion
% of Total Assets 74.54%
Annual Growth Rate 2.96%
5-Year Change -16.07%
10-Year Change 7.28%
Growth Volatility 7.2

Kyung Dong Pharmaceutical Co. Ltd - Net Assets Trend (2011–2024)

This chart illustrates how Kyung Dong Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Kyung Dong Pharmaceutical Co. Ltd (2011–2024)

The table below shows the annual net assets of Kyung Dong Pharmaceutical Co. Ltd from 2011 to 2024.

Year Net Assets Change
2024-12-31 ₩220.06 Billion -3.68%
2023-12-31 ₩228.48 Billion -11.17%
2022-12-31 ₩257.20 Billion -1.01%
2021-12-31 ₩259.82 Billion -0.90%
2020-12-31 ₩262.19 Billion +15.65%
2019-12-31 ₩226.71 Billion +7.08%
2018-12-31 ₩211.72 Billion -4.18%
2017-12-31 ₩220.95 Billion +5.25%
2016-12-31 ₩209.93 Billion +2.34%
2015-12-31 ₩205.14 Billion +7.72%
2014-12-31 ₩190.43 Billion +12.66%
2013-12-31 ₩169.03 Billion +9.93%
2012-12-31 ₩153.76 Billion +2.09%
2011-12-31 ₩150.62 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Kyung Dong Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 19329937689000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩193.30 Billion 87.84%
Common Stock ₩15.68 Billion 7.13%
Other Components ₩11.08 Billion 5.03%
Total Equity ₩220.06 Billion 100.00%

Kyung Dong Pharmaceutical Co. Ltd Competitors by Market Cap

The table below lists competitors of Kyung Dong Pharmaceutical Co. Ltd ranked by their market capitalization.

Company Market Cap
Tembo Global Industries Limited
NSE:TEMBO
 		$50.06 Million
Saksiam Leasing Public Company Limited
BK:SAK
 		$50.08 Million
Peter Warren Automotive Holdings Ltd
AU:PWR
 		$50.08 Million
Silk Logistics Holdings Ltd
AU:SLH
 		$50.08 Million
T.K.S. Technologies Public Company Limited
BK:TKS
 		$50.05 Million
ImageneBio, Inc.
NASDAQ:IMA
 		$50.02 Million
Cameo Communications Inc
TW:6142
 		$50.00 Million
ReaLy Development & Construction
TWO:2596
 		$50.00 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Kyung Dong Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 228,178,978,830 to 220,060,755,990, a change of -8,118,222,840 (-3.6%).
  • Net income of 5,469,651,900 contributed positively to equity growth.
  • Dividend payments of 10,853,508,000 reduced retained earnings.
  • Share repurchases of 1,240,121,750 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩5.47 Billion +2.49%
Dividends Paid ₩10.85 Billion -4.93%
Share Repurchases ₩1.24 Billion -0.56%
Other Changes ₩-1.49 Billion -0.68%
Total Change ₩- -3.56%

Book Value vs Market Value Analysis

This analysis compares Kyung Dong Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.67x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩8926.12 ₩5470.00 x
2017-12-31 ₩9371.12 ₩5470.00 x
2018-12-31 ₩8941.38 ₩5470.00 x
2019-12-31 ₩9574.44 ₩5470.00 x
2020-12-31 ₩9461.29 ₩5470.00 x
2021-12-31 ₩9540.40 ₩5470.00 x
2022-12-31 ₩9468.64 ₩5470.00 x
2023-12-31 ₩8409.41 ₩5470.00 x
2024-12-31 ₩8168.01 ₩5470.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Kyung Dong Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.49%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 2.82%
  • • Asset Turnover: 0.64x
  • • Equity Multiplier: 1.38x
  • Recent ROE (2.49%) is below the historical average (6.18%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 13.47% 15.94% 0.69x 1.23x ₩5.23 Billion
2012 5.34% 6.60% 0.66x 1.23x ₩-7.17 Billion
2013 11.13% 14.17% 0.66x 1.18x ₩1.91 Billion
2014 12.89% 16.00% 0.67x 1.20x ₩5.49 Billion
2015 6.89% 9.30% 0.65x 1.14x ₩-6.38 Billion
2016 8.39% 11.10% 0.67x 1.14x ₩-3.38 Billion
2017 9.27% 11.52% 0.71x 1.14x ₩-1.62 Billion
2018 2.48% 2.92% 0.70x 1.22x ₩-15.93 Billion
2019 8.88% 11.40% 0.61x 1.27x ₩-2.54 Billion
2020 4.75% 7.17% 0.60x 1.11x ₩-13.76 Billion
2021 4.88% 7.13% 0.61x 1.12x ₩-13.31 Billion
2022 4.73% 6.66% 0.59x 1.21x ₩-13.56 Billion
2023 -9.08% -12.73% 0.56x 1.28x ₩-43.53 Billion
2024 2.49% 2.82% 0.64x 1.38x ₩-16.54 Billion

Industry Comparison

This section compares Kyung Dong Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

  • Industry: Pharmaceuticals
  • Average net assets among peers: $78,306,792,589
  • Average return on equity (ROE) among peers: -11.11%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Kyung Dong Pharmaceutical Co. Ltd (011040) ₩217.26 Billion 13.47% 0.34x $50.06 Million
Sam Chun Dang Pharm. Co. Ltd (000250) $114.32 Billion 10.17% 0.61x $3.69 Billion
DongKoo Bio&Pharma Co. Ltd (006620) $94.65 Billion 9.66% 0.53x $57.77 Million
NatureCell Co.Ltd (007390) $34.02 Billion -9.48% 0.55x $37.82 Million
Sam-A Pharm. Co. Ltd (009300) $148.92 Billion 6.63% 0.09x $21.27 Million
WooGene B&G Co. Ltd (018620) $26.51 Billion -25.02% 1.26x $10.61 Million
Oscotec Inc (039200) $28.83 Billion -91.10% 0.70x $890.75 Million
EstechPharma Co. Ltd (041910) $123.30 Billion 5.58% 0.09x $50.99 Million
Komipharm International Co. Ltd (041960) $93.39 Billion -15.32% 0.50x $237.27 Million
Eagle Veterinary Technology Co.Ltd (044960) $40.83 Billion 8.91% 0.29x $20.48 Million